Literature DB >> 19425057

The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism.

John DePaolo1, Ozlem Goker-Alpan, Ted Samaddar, Grisel Lopez, Ellen Sidransky.   

Abstract

A body of work has emerged over the past decade demonstrating a relationship between mutations in glucocerebrosidase gene (GBA), the gene implicated in Gaucher disease (GD), and the development of parkinsonism. Several different lines of research support this relationship. First, patients with GD who are homozygous for mutations in GBA have a higher than expected propensity to develop Parkinson's disease (PD). Furthermore, carriers of GBA mutations, particularly family members of patients with GD, have displayed an increased rate of parkinsonism. Subsequently, investigators from centers around the world screened cohorts of patients with parkinsonism for GBA mutations and found that overall, subjects with PD, as well as other Lewy body disorders, have at least a fivefold increase in the number of carriers of GBA mutations as compared to age-matched controls. In addition, neuropathologic studies of subjects with parkinsonism carrying GBA mutations demonstrate Lewy bodies, depletion of neurons of the substantia nigra, and involvement of hippocampal layers CA2-4. Although the basis for this association has yet to be elucidated, evidence continues to support the role of GBA as a PD risk factor across different centers, synucleinopathies, and ethnicities. Further studies of the association between GD and parkinsonism will stimulate new insights into the pathophysiology of the two disorders and will prove crucial for both genetic counseling of patients and family members and the design of relevant therapeutic strategies for specific patients with parkinsonism. 2009 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19425057      PMCID: PMC2736332          DOI: 10.1002/mds.22538

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  50 in total

1.  Parkinson's syndrome preceding clinical manifestation of Gaucher's disease.

Authors:  M Machaczka; M Rucinska; A B Skotnicki; W Jurczak
Journal:  Am J Hematol       Date:  1999-07       Impact factor: 10.047

2.  The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews.

Authors:  Michael J Eblan; Jamie M Walker; Ellen Sidransky
Journal:  N Engl J Med       Date:  2005-02-17       Impact factor: 91.245

3.  The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews.

Authors:  Michael G Schlossmacher; Valerie Cullen; Johannes Müthing
Journal:  N Engl J Med       Date:  2005-02-17       Impact factor: 91.245

4.  Parkinsonism among Gaucher disease carriers.

Authors:  O Goker-Alpan; R Schiffmann; M E LaMarca; R L Nussbaum; A McInerney-Leo; E Sidransky
Journal:  J Med Genet       Date:  2004-12       Impact factor: 6.318

Review 5.  Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia.

Authors:  J Q Trojanowski; M Goedert; T Iwatsubo; V M Lee
Journal:  Cell Death Differ       Date:  1998-10       Impact factor: 15.828

6.  Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews.

Authors:  Judith Aharon-Peretz; Hanna Rosenbaum; Ruth Gershoni-Baruch
Journal:  N Engl J Med       Date:  2004-11-04       Impact factor: 91.245

7.  Occurrence of Parkinson's syndrome in type I Gaucher disease.

Authors:  O Neudorfer; N Giladi; D Elstein; A Abrahamov; T Turezkite; E Aghai; A Reches; B Bembi; A Zimran
Journal:  QJM       Date:  1996-09

8.  Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity.

Authors:  Lorraine N Clark; Angelique Nicolai; Shehla Afridi; Juliette Harris; Helen Mejia-Santana; Lisa Strug; Lucien J Cote; Elan D Louis; Howard Andrews; Cheryl Waters; Blair Ford; Steven Frucht; Stanley Fahn; Richard Mayeux; Ruth Ottman; K Marder
Journal:  Mov Disord       Date:  2005-01       Impact factor: 10.338

9.  alpha-synuclein is required for the fibrillar nature of ubiquitinated inclusions induced by proteasomal inhibition in primary neurons.

Authors:  Hardy J Rideout; Paula Dietrich; Qiaohong Wang; William T Dauer; Leonidas Stefanis
Journal:  J Biol Chem       Date:  2004-08-18       Impact factor: 5.157

10.  Type 2 and type 3 Gaucher disease: a morphological and biochemical study.

Authors:  E M Kaye; M D Ullman; E R Wilson; J A Barranger
Journal:  Ann Neurol       Date:  1986-08       Impact factor: 10.422

View more
  27 in total

Review 1.  Missing pieces in the Parkinson's disease puzzle.

Authors:  Jose A Obeso; Maria C Rodriguez-Oroz; Christopher G Goetz; Concepcion Marin; Jeffrey H Kordower; Manuel Rodriguez; Etienne C Hirsch; Matthew Farrer; Anthony H V Schapira; Glenda Halliday
Journal:  Nat Med       Date:  2010-05-23       Impact factor: 53.440

2.  A lysosomal lair for a pathogenic protein pair.

Authors:  Ted M Dawson; Valina L Dawson
Journal:  Sci Transl Med       Date:  2011-07-13       Impact factor: 17.956

Review 3.  Cognitive impairment and dementia in patients with Parkinson disease.

Authors:  James B Leverenz; Joseph F Quinn; Cyrus Zabetian; Jing Zhang; Kathleen S Montine; Thomas J Montine
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

4.  Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

Authors:  E Sidransky; M A Nalls; J O Aasly; J Aharon-Peretz; G Annesi; E R Barbosa; A Bar-Shira; D Berg; J Bras; A Brice; C-M Chen; L N Clark; C Condroyer; E V De Marco; A Dürr; M J Eblan; S Fahn; M J Farrer; H-C Fung; Z Gan-Or; T Gasser; R Gershoni-Baruch; N Giladi; A Griffith; T Gurevich; C Januario; P Kropp; A E Lang; G-J Lee-Chen; S Lesage; K Marder; I F Mata; A Mirelman; J Mitsui; I Mizuta; G Nicoletti; C Oliveira; R Ottman; A Orr-Urtreger; L V Pereira; A Quattrone; E Rogaeva; A Rolfs; H Rosenbaum; R Rozenberg; A Samii; T Samaddar; C Schulte; M Sharma; A Singleton; M Spitz; E-K Tan; N Tayebi; T Toda; A R Troiano; S Tsuji; M Wittstock; T G Wolfsberg; Y-R Wu; C P Zabetian; Y Zhao; S G Ziegler
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

Review 5.  Neuropathic Gaucher disease.

Authors:  Gregory M Pastores
Journal:  Wien Med Wochenschr       Date:  2010-12

6.  NMR Metabolomics Analysis of Parkinson's Disease.

Authors:  Shulei Lei; Robert Powers
Journal:  Curr Metabolomics       Date:  2013

Review 7.  Genetic convergence of Parkinson's disease and lysosomal storage disorders.

Authors:  Hao Deng; Xiaofei Xiu; Joseph Jankovic
Journal:  Mol Neurobiol       Date:  2014-08-07       Impact factor: 5.590

8.  Intravenous infusion of iPSC-derived neural precursor cells increases acid β-glucosidase function in the brain and lessens the neuronopathic phenotype in a mouse model of Gaucher disease.

Authors:  Yanyan Peng; Benjamin Liou; Venette Inskeep; Rachel Blackwood; Christopher N Mayhew; Gregory A Grabowski; Ying Sun
Journal:  Hum Mol Genet       Date:  2019-10-15       Impact factor: 6.150

9.  Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease.

Authors:  Karen E Murphy; Amanda M Gysbers; Sarah K Abbott; Nahid Tayebi; Woojin S Kim; Ellen Sidransky; Antony Cooper; Brett Garner; Glenda M Halliday
Journal:  Brain       Date:  2014-01-28       Impact factor: 13.501

Review 10.  Gaucher disease: insights from a rare Mendelian disorder.

Authors:  Ellen Sidransky
Journal:  Discov Med       Date:  2012-10       Impact factor: 2.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.